124 related articles for article (PubMed ID: 1311025)
1. Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group.
Arriagada R; Kramar A; Le Chevalier T; De Cremoux H
J Clin Oncol; 1992 Mar; 10(3):447-51. PubMed ID: 1311025
[TBL] [Abstract][Full Text] [Related]
2. Alternating radiotherapy and chemotherapy in limited small cell lung cancer: the IGR protocols. French FNCLCC Lung Cancer Study Group.
Arriagada R; Le Chevalier T; Ruffié P; Chomy P; de Cremoux H
Lung Cancer; 1994 Mar; 10 Suppl 1():S289-98. PubMed ID: 8087522
[TBL] [Abstract][Full Text] [Related]
3. Alternating radiotherapy and chemotherapy in 173 consecutive patients with limited small cell lung carcinoma. GROP and the French Cancer Center's Lung Group.
Arriagada R; le Chevalier T; Ruffie P; Baldeyrou P; De Cremoux H; Martin M; Chomy P; Cerrina ML; Pellae-Cosset B; Tarayre M
Int J Radiat Oncol Biol Phys; 1990 Nov; 19(5):1135-8. PubMed ID: 2174838
[TBL] [Abstract][Full Text] [Related]
4. Combination of chemotherapy and radiotherapy in limited small cell lung carcinoma: results of alternating schedule in 109 patients.
Le Chevalier T; Arriagada R; de Thé H; De Cremoux H; Martin M; Baldeyrou P; Ruffié P; Benna F; Cerrina ML; Sancho-Garnier H
NCI Monogr; 1988; (6):335-8. PubMed ID: 2832769
[TBL] [Abstract][Full Text] [Related]
5. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
6. Limited small cell lung cancer: possible prognostic impact of initial chemotherapy doses.
Arriagada R; de The H; Le Chevalier T; Thomas F; Ruffie P; de Cremoux H; Martin M; Duroux P; Dewar J; Sancho-Garnier H
Bull Cancer; 1989; 76(6):604-15. PubMed ID: 2550102
[TBL] [Abstract][Full Text] [Related]
7. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
8. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
[TBL] [Abstract][Full Text] [Related]
9. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
11. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
Thomas F; Arriagada R; Spielmann M; Mouriesse H; Le Chevalier T; Fontaine F; Tursz T
Cancer; 1995 Dec; 76(11):2286-90. PubMed ID: 8635033
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study.
Gregor A; Drings P; Burghouts J; Postmus PE; Morgan D; Sahmoud T; Kirkpatrick A; Dalesio O; Giaccone G
J Clin Oncol; 1997 Aug; 15(8):2840-9. PubMed ID: 9256127
[TBL] [Abstract][Full Text] [Related]
13. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
Schild SE; Bonner JA; Hillman S; Kozelsky TF; Vigliotti AP; Marks RS; Graham DL; Soori GS; Kugler JW; Tenglin RC; Wender DB; Adjei A
J Clin Oncol; 2007 Jul; 25(21):3124-9. PubMed ID: 17634491
[TBL] [Abstract][Full Text] [Related]
15. [Chemo-radiotherapy combination in small cell bronchial carcinomas. Limitations and results in 109 patients treated with an alternating protocol].
Le Chevalier T; Arriagada R; Baldeyrou P; de Cremoux H; Ruffié P; Martin M; Cerrina ML; de Thé G; Sancho-Garnier H; Hayat M
Bull Cancer; 1987; 74(5):559-64. PubMed ID: 2825857
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group.
Lebeau B; Urban T; Bréchot JM; Paillotin D; Vincent J; Leclerc P; Meekel P; L'Her P; Lebas FX; Chastang C
Cancer; 1999 Oct; 86(8):1480-7. PubMed ID: 10526276
[TBL] [Abstract][Full Text] [Related]
17. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
[TBL] [Abstract][Full Text] [Related]
18. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
Turrisi AT; Kim K; Blum R; Sause WT; Livingston RB; Komaki R; Wagner H; Aisner S; Johnson DH
N Engl J Med; 1999 Jan; 340(4):265-71. PubMed ID: 9920950
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
20. Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer.
Kamath SS; McCarley DL; Zlotecki RA
Radiat Oncol Investig; 1998; 6(5):226-32. PubMed ID: 9822169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]